Georg Buchner, formerly vice president of corporate and business development at Novacta Biosystems Ltd, is joining Silence Therapeutics Plc as vice president of business development. Dr Buchner will work with Tony Sedgwick, who was appointed Silence’s chief business officer in September. Prior to joining Novacta, Dr Buchner was business development director at Haptogen Ltd and was instrumental in the sale of the business to Wyeth (now part of Pfizer) in 2007.
Copyright 2011 Evernow Publishing Ltd